One-glance verdict
Within fair range
$0.94 our estimate vs market $0.82
Wall Street consensus: $2.00 (113.8% higher than our fair-value estimate)
12% below our estimate
Fundamentals snapshot
Organogenesis Holdings Inc.
ORGO · NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Current price
$0.82
52-week range
$0.81 - $7.08
Market cap
$105.37M
Balance sheet
Healthy
36.18x Strong cushion
Net debt $20.85M. Interest coverage shows how many times profit covers the interest bill.
What stands out
1 Reward
2 Risks
1 rewards · 2 risks
- Reward Free cash flow was positive in 3/10 years.
- Risk Operating margin compressed from 4.9% to -119.3% over 3 years.
- Risk Return on equity was -25.9% last year — the company lost money on shareholders' equity.
What this company does
Organogenesis Holdings Inc.
Organogenesis Holdings Inc. sells products made from human placental tissue to help heal serious wounds and in surgeries, with the money primarily coming from selling these advanced medical treatments. This matters because their specialized products help patients recover faster and can be a key part of treating difficult medical conditions.
How the company got here
Organogenesis Holdings Inc. is a company focused on regenerative medicine, which means it creates products that help the body heal itself. It started by developing innovative treatments for wound care, aiming to help patients with difficult-to-heal injuries. Over time, the company has expanded its offerings to include solutions for surgical needs and sports-related injuries, building on its expertise in tissue engineering and biomaterials. This evolution has positioned Organogenesis as a key player in the healthcare market, offering advanced solutions beyond traditional treatments.
What it actually does
Organogenesis develops and sells products designed to help the body repair damaged tissues. Think of them as creating advanced bandages and skin substitutes that go beyond simple coverings. These products use natural materials from placentas or engineered tissues to provide a scaffold that encourages the body's own healing processes. They are used to treat a variety of conditions, from chronic wounds like diabetic foot ulcers to surgical sites and sports injuries, helping patients recover faster and more effectively.
Advanced Wound Care
This is the largest part of Organogenesis's business, focusing on products for chronic and acute wounds. These include specialized skin substitutes and placental tissue grafts, like Apligraf and Novachor, that act as protective barriers and provide a framework for new tissue growth. They are used to treat serious conditions such as venous leg ulcers and diabetic foot ulcers, which are often slow to heal. This segment aims to improve patient outcomes by accelerating the natural healing process and reducing the risk of infection.
Surgical and Sports Medicine
Organogenesis also offers products for surgical procedures and recovery, as well as for sports-related injuries. This includes materials like PuraForce, a bioengineered collagen matrix used to reinforce soft tissues during surgery, and products that help manage open wounds in surgical settings. For sports medicine, their technologies can aid in the healing of muscle and tissue damage. This segment leverages the company's regenerative medicine expertise to support healing in a broader range of medical applications.
What management is betting on now
Management is focused on expanding the use of their existing regenerative medicine products and developing new ones. A key area of development is ReNu, a treatment for knee osteoarthritis symptoms currently in late-stage clinical trials. The company is also working to grow its presence in both the advanced wound care and surgical markets. By continuing to innovate and bring new therapies to market, Organogenesis aims to address unmet medical needs and drive future growth.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$6.13M
FY2024 Q4
$7.58M
FY2025 Q1
$-23.56M
FY2025 Q2
$-36.51M
FY2025 Q3
$844.00K
FY2025 Q4
$34.77M
FY2026 Q1
$17.98M
FY2026 Q2
$-32.75M
Revenue
$43.76M
Net income
$-96.27M
Diluted EPS
-0.77
Operating cash flow
$-31.65M
Free cash flow
$-32.75M
Fetching…
Sources
Revenue
$37.23M
Net income
$-53.16M
Diluted EPS
-0.44
Operating cash flow
$21.13M
Free cash flow
$17.98M
Fetching…
Sources
Revenue
$225.61M
Net income
$43.70M
Diluted EPS
0.31
Operating cash flow
$39.42M
Free cash flow
$34.77M
Fetching…
Sources
Revenue
$150.86M
Net income
$21.57M
Diluted EPS
0.11
Operating cash flow
$3.08M
Free cash flow
$844.00K
Fetching…
Sources
Revenue
$101.00M
Net income
$-9.39M
Diluted EPS
-0.10
Operating cash flow
$-32.87M
Free cash flow
$-36.51M
Fetching…
Sources
Revenue
$86.69M
Net income
$-18.84M
Diluted EPS
-0.17
Operating cash flow
$-19.93M
Free cash flow
$-23.56M
Fetching…
Sources
Revenue
$126.66M
Net income
$7.67M
Diluted EPS
0.05
Operating cash flow
$10.94M
Free cash flow
$7.58M
Fetching…
Sources
Revenue
$115.18M
Net income
$12.33M
Diluted EPS
0.09
Operating cash flow
$8.70M
Free cash flow
$6.13M
Fetching…
Sources
Is it cheap or expensive?
Fair value $0.94 vs current price $0.82
Wall Street consensus is the average analyst price target: $2.00 (113.8% higher than our fair-value estimate).
Our most-likely fair value is $0.94 a share — about 14.2% away from today's price of $0.82, so the stock currently looks fairly priced.
Is it drowning in debt?
Healthy
Net debt $20.9M. Interest coverage 36.2x.
Net debt
$20.85M
Interest coverage
36.18x
Organogenesis Holdings Inc.'s profit covers its interest bill about 36.2 times over. which is stronger than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ORGO
BASELINE
Organogenesis Holdings Inc.
Total debt $66.95M Interest coverage 36.18x This is the baseline the peer rows are being compared against.
Total debt $8.61M Interest coverage -66.52x -100% vs ORGO This peer has almost no interest-payment cushion compared with ORGO.
Total debt $25.25M Interest coverage -6.34x -100% vs ORGO This peer has almost no interest-payment cushion compared with ORGO.
Total debt $48.48M Interest coverage -8.50x -100% vs ORGO This peer has almost no interest-payment cushion compared with ORGO.
Total debt $17.21M Interest coverage 63.51x +76% vs ORGO Carries about 1.8x more debt cushion than ORGO.
Total debt $1.22M Interest coverage 53.13x +47% vs ORGO Carries about 1.5x more debt cushion than ORGO.
What you should know
The case for and against ORGO
1 Reward
2 Risks
Rewards
-
Free cash flow was positive in 3/10 years.
Risks
-
Operating margin compressed from 4.9% to -119.3% over 3 years.
-
Return on equity was -25.9% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-2.64x
P/B
0.71x
P/S
0.23x
EV/EBITDA
-27.43x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
71.5%
Operating margin
-119.3%
Net margin
-18.4%
ROE
-25.9%
ROA
-4.1%
Health
Liquidity and balance-sheet strength
Debt / equity
0.23x
Current ratio
3.52x
Quick ratio
2.58x
Total debt
$66.95M
Total cash
$46.10M
Growth
How the business has been compounding
Revenue TTM
$457.45M
Revenue 5Y CAGR
4.8%
EPS TTM
-0.83
EPS 5Y CAGR
7.7%
Cash flow
How much cash the business throws off
Operating CF TTM
$31.97M
Free CF TTM
$-24.46M
FCF margin
-5.3%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—